Drug intelligence / Profile preview

MU-D201

Development stage: Preclinical
Lead developer: MedPacto
Modality: Small Molecules

Overview

MU-D201 is a small molecule inhibitor of DAP kinase-related apoptosis-inducing kinase-2 (DRAK2) currently under preclinical development by MedPacto. DRAK2 is a serine/threonine kinase that, when overexpressed, promotes cancer cell growth and metastasis by regulating TGF-β signaling and modulating the activity of the epigenetic regulator enhancer of zeste homolog 2 (EZH2). MU-D201 is specifically being investigated for the treatment of diffuse large B-cell lymphoma (DLBCL), particularly cases involving EZH2 mutations, and gamma delta T-cell leukemia. Preclinical animal studies have demonstrated its ability to suppress tumor growth and metastasis by targeting these signaling and epigenetic pathways.

Targets

STK17B (Serine/threonine kinase 17b)

Beyond the preview

Go deeper on MU-D201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MU-D201.

Explore the full profile